| Follow-up | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Visit number | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 |
Month | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
Inclusion and exclusion criteria | x | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Framingham score | x | Â | Â | x | Â | Â | Â | Â | Â | Â | Â | Â | x |
Estimated 24-hour salt intake, overnight urine | x | Â | Â | x | Â | Â | Â | Â | Â | Â | Â | Â | x |
Blood pressure | x | x | x | x | x | x | x | x | x | x | x | x | x |
Body composition | x | Â | Â | x | Â | Â | Â | Â | Â | Â | Â | Â | x |
Blood glucose | x | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
HbA1c | x | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Lipid profile | x | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
BUN, creatinine | x | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Sodium, potassium | x | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Uric acid | x | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
CVD event | x | Â | Â | x | Â | Â | Â | Â | Â | Â | Â | Â | x |
CVD death | x | Â | Â | x | Â | Â | Â | Â | Â | Â | Â | Â | x |
Retinal caliber | x | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Demographic characteristics | x | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Questionnaires assessing behavioral change | x | Â | Â | x | Â | Â | Â | Â | Â | Â | Â | Â | x |
Questionnaires assessing health costs | x | Â | Â | x | Â | Â | Â | Â | Â | Â | Â | Â | x |